5-Methyl-7,8-dihydrochinolin | 60499-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-Methyl-7,8-dihydrochinolin
• 英文别名: 5-methyl-7,8-dihydro-quinoline；5-Methyl-7,8-dihydroquinoline
• CAS: 60499-13-0
• 化学式: C₁₀H₁₁N
• 分子量: 145.204
• InChiKey: GQZYZTDUXZYRJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF<br/>[FR] INHIBITEURS DE SHP2, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：BETTA PHARMACEUTICALS CO LTD

  公开号：WO2021249449A1

  公开（公告）日：2021-12-16

  Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

  提供的是式（I）的化合物，使用这些化合物作为SHP2抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗SHP2介导的疾病方面是有用的。
• INHIBITORS OF IAP
  申请人：Flygare John A.

  公开号：US20110077265A1

  公开（公告）日：2011-03-31

  The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3′, R4, R4′ and R5, are as described herein.

  本发明提供了IAP的新型抑制剂，可用作治疗恶性肿瘤的治疗剂，其中化合物具有一般式U1-M-U2，其中M是连接U1的R2、R3、R4或R5与U2的R2、R3、R4或R5基团的连接基团；U1和U2具有一般式（I），G、X1、X2、R2、R3、R3'、R4、R4'和R5如本文所述。
• [EN] COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN HDAC INHIBITOR<br/>[FR] POLYTHÉRAPIE DESTINÉE À TRAITER LE CANCER COMPRENANT UN INHIBITEUR DE L'IGF-1R ET UN INHIBITEUR DE LA HDAC
  申请人：UNIV TEXAS

  公开号：WO2011097166A2

  公开（公告）日：2011-08-11

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of an IGF-1R inhibitor in a first treatment procedure and a second amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount.